TRPA1 and breast cancer: Conversely, blocking TRPA1-mediated Ca2+ signals to prevent the recruitment of non-canonical antioxidant programs (e.g., in lung and breast cancers) would limit TRPA1-induced ROS production, thereby either increasing (if TRPA1-dependent ROS are pro-tumorigenic) or tempering (if TRPA1-dependent ROS are pro-apoptotic) the therapeutic impact of TRPA1 manipulation.